Aurinia Pharmaceuticals Inc [AUPH] stock is trading at $7.20, up 2.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AUPH shares have gain 1.69% over the last week, with a monthly amount glided 7.30%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] stock has seen the most recent analyst activity on November 04, 2022, when Oppenheimer downgraded its rating to a Perform. On December 10, 2021, upgrade upgraded it’s rating to Outperform and revised its price target to $31 on the stock. Oppenheimer downgraded its rating to a Perform but stick to its price target of $32 on October 28, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $35 on January 25, 2021. H.C. Wainwright reiterated a Buy rating for this stock on November 03, 2020, and downed its price target to $28. In a note dated June 17, 2020, BTIG Research initiated an Buy rating and provided a target price of $20 on this stock.
Aurinia Pharmaceuticals Inc [AUPH] stock has fluctuated between $4.71 and $10.05 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. Aurinia Pharmaceuticals Inc [NASDAQ: AUPH] shares were valued at $7.20 at the most recent close of the market. An investor can expect a potential return of 49.31% based on the average AUPH price forecast.
Analyzing the AUPH fundamentals
Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] reported sales of 207.11M for the trailing twelve months, which represents a growth of 37.83%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.23%, and Net Profit Margin reading is -0.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.13 and Total Capital is -0.11. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.02 points at the first support level, and at 6.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.29, and for the 2nd resistance point, it is at 7.38.
Ratios To Look Out For
For context, Aurinia Pharmaceuticals Inc’s Current Ratio is 5.33. As well, the Quick Ratio is 4.82, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 4.97, the price to book ratio is 2.82.
Transactions by insiders
Recent insider trading involved Habig Scott Michael, Chief Commercial Officer, that happened on Aug 06 ’24 when 18249.0 shares were sold. Director, Balakrishnan Brinda completed a deal on May 21 ’24 to sell 520.0 shares. Meanwhile, Director Billen Daniel sold 5252.0 shares on May 21 ’24.
